Ashland to acquire International Specialty Products for $3.2 billion

1 June 2011

USA-based Ashland (NYSE: ASH) has agreed to acquire privately-held International Specialty Products (ISP), a global specialty chemical manufacturer of innovative functional ingredients and technologies. Under the terms of the stock purchase deal, Ashland will pay around $3.2 billion for the business in an all-cash transaction.

At closing, ISP's advanced product portfolio will expand Ashland's position in high-growth markets such as personal care, pharmaceuticals and energy. For the 12 months ended March 31, 2011, ISP generated sales of about $1.6 billion and earnings before interest, taxes, depreciation and amortization (EBITDA) of some $360 million. The transaction is expected to be immediately accretive to Ashland's earnings per share.

The acquisition is expected to significantly strengthen Ashland's functional ingredients active patent portfolio and its team of R&D scientists. The result will be a stronger, global functional ingredients business with proven technological and application capabilities to solve customers' unique formulation challenges, Ashland states.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical